NEW YORK (TheStreet) -- In Friday's CNBC segment of "Stop Trading," TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, called InterMune (ITMN) a buy. He sure looks right. Currently, the stock is higher by more than 13%.
"The New England Journal of Medicine came out with a very positive piece on Sunday," about InterMune, Cramer said.
He called the company's pulmonary fibrosis treatment a "drug I truly believe in," and suggested that "InterMune goes higher."
Turning to Zillow (Z), Cramer reasoned that the stock could move higher and appears to be breaking out.With a short interest north of 37%, a "short squeeze to end all short squeezes" may be in the cards if the stock can push above $111. >>Read More: AT&T's Bid Flunks Verizon Dividend Test >>Read More: Google Is Close to a Deal for Twitch >>Read More: Best of Kass: Deadhead Tips; 10-Year Yields -- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell At the time of publication, the author held no positions in any of the stocks mentioned. This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV